Volume 34, Issue 28
Research Article

The power prior: theory and applications

Joseph G. Ibrahim

Corresponding Author

Department of Biostatistics, University of North Carolina, Chapel Hill, 27599 NC, U.S.A.

Correspondence to: Joseph G. Ibrahim, Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, U.S.A.

E‐mail: ibrahim@bios.unc.edu

Search for more papers by this author
Ming‐Hui Chen

Department of Statistics, University of Connecticut, Storrs, CT, 06269 U.S.A.

Search for more papers by this author
Yeongjin Gwon

Department of Statistics, University of Connecticut, Storrs, CT, 06269 U.S.A.

Search for more papers by this author
Fang Chen

SAS Institute Inc., Cary, NC, U.S.A.

Search for more papers by this author
First published: 07 September 2015
Citations: 51

Abstract

The power prior has been widely used in many applications covering a large number of disciplines. The power prior is intended to be an informative prior constructed from historical data. It has been used in clinical trials, genetics, health care, psychology, environmental health, engineering, economics, and business. It has also been applied for a wide variety of models and settings, both in the experimental design and analysis contexts. In this review article, we give an A‐to‐Z exposition of the power prior and its applications to date. We review its theoretical properties, variations in its formulation, statistical contexts for which it has been used, applications, and its advantages over other informative priors. We review models for which it has been used, including generalized linear models, survival models, and random effects models. Statistical areas where the power prior has been used include model selection, experimental design, hierarchical modeling, and conjugate priors. Frequentist properties of power priors in posterior inference are established, and a simulation study is conducted to further examine the empirical performance of the posterior estimates with power priors. Real data analyses are given illustrating the power prior as well as the use of the power prior in the Bayesian design of clinical trials. Copyright © 2015 John Wiley & Sons, Ltd.

Number of times cited according to CrossRef: 51

  • A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival, Critical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2020.102896, (102896), (2020).
  • START: single‐to‐double arm transition design for phase II clinical trials, Pharmaceutical Statistics, 10.1002/pst.2005, 19, 4, (454-467), (2020).
  • Monte Carlo Simulation for Trial Design Tool, Principles and Practice of Clinical Trials, 10.1007/978-3-319-52677-5, (1-23), (2020).
  • Incorporating historical two‐arm data in clinical trials with binary outcome: A practical approach, Pharmaceutical Statistics, 10.1002/pst.2023, 19, 5, (662-678), (2020).
  • PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials, Biometrics, 10.1111/biom.13217, 0, 0, (2020).
  • A Bayesian approach in design and analysis of pediatric cancer clinical trials, Pharmaceutical Statistics, 10.1002/pst.2039, 0, 0, (2020).
  • Optimality of testing procedures for survival data in the nonproportional hazards setting, Biometrics, 10.1111/biom.13315, 0, 0, (2020).
  • Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies, Health Services and Outcomes Research Methodology, 10.1007/s10742-020-00218-4, (2020).
  • Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control, Biometrical Journal, 10.1002/bimj.201800395, 62, 2, (361-374), (2019).
  • Optimal designs for regional bridging studies using the Bayesian power prior method, Pharmaceutical Statistics, 10.1002/pst.1967, 19, 1, (22-30), (2019).
  • Quantification of prior impact in terms of effective current sample size, Biometrics, 10.1111/biom.13124, 76, 1, (326-336), (2019).
  • A comparison of Bayesian synthesis approaches for studies comparing two means: A tutorial, Research Synthesis Methods, 10.1002/jrsm.1365, 11, 1, (36-65), (2019).
  • Examining overlap of included studies in meta‐reviews: Guidance for using the corrected covered area index, Research Synthesis Methods, 10.1002/jrsm.1390, 11, 1, (134-145), (2019).
  • Dealing with missing outcome data in meta‐analysis, Research Synthesis Methods, 10.1002/jrsm.1349, 11, 1, (2-13), (2019).
  • Shared parameter model for competing risks and different data summaries in meta‐analysis: Implications for common and rare outcomes, Research Synthesis Methods, 10.1002/jrsm.1371, 11, 1, (91-104), (2019).
  • Pathway‐based meta‐analysis for partially paired transcriptomics analysis, Research Synthesis Methods, 10.1002/jrsm.1381, 11, 1, (123-133), (2019).
  • Random‐effects meta‐analysis of few studies involving rare events, Research Synthesis Methods, 10.1002/jrsm.1370, 11, 1, (74-90), (2019).
  • The dark side of the force: Multiplicity issues in network meta‐analysis and how to address them, Research Synthesis Methods, 10.1002/jrsm.1377, 11, 1, (105-122), (2019).
  • Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned, Pharmaceutical Statistics, 10.1002/pst.1941, 18, 4, (486-506), (2019).
  • Risk-based Approach to Lot Release, Journal of Pharmaceutical Sciences, 10.1016/j.xphs.2019.10.011, (2019).
  • A Bayesian Constancy-Enforced Non-Inferiority Design in Medical Device Trials with a Binary Endpoint, Contemporary Biostatistics with Biopharmaceutical Applications, 10.1007/978-3-030-15310-6_13, (239-249), (2019).
  • CRM2DIM: A SAS macro for implementing the Dual-Agent Bayesian Continual Reassessment Method, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2019.04.025, (2019).
  • Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints, Statistics in Biopharmaceutical Research, 10.1080/19466315.2019.1610043, (1-15), (2019).
  • Bayesian Extended Redundancy Analysis: A Bayesian Approach to Component-based Regression with Dimension Reduction, Multivariate Behavioral Research, 10.1080/00273171.2019.1598837, (1-19), (2019).
  • An adaptive power prior for sequential clinical trials – Application to bridging studies, Statistical Methods in Medical Research, 10.1177/0962280219886609, (096228021988660), (2019).
  • Power priors based on multiple historical studies for binary outcomes, Biometrical Journal, 10.1002/bimj.201700246, 61, 5, (1201-1218), (2018).
  • Predictive probability of success using surrogate endpoints, Statistics in Medicine, 10.1002/sim.8060, 38, 10, (1753-1774), (2018).
  • Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies, Statistical Methods in Medical Research, 10.1177/0962280218754928, 28, 5, (1293-1310), (2018).
  • Bayesian sample size re-estimation using power priors, Statistical Methods in Medical Research, 10.1177/0962280218772315, 28, 6, (1664-1675), (2018).
  • Bayesian design of a survival trial with a cured fraction using historical data, Statistics in Medicine, 10.1002/sim.7846, 37, 26, (3814-3831), (2018).
  • A practical Bayesian adaptive design incorporating data from historical controls, Statistics in Medicine, 10.1002/sim.7897, 37, 27, (4054-4070), (2018).
  • A Bayesian Analysis of Design Parameters in Survey Data Collection, Journal of Survey Statistics and Methodology, 10.1093/jssam/smy012, 6, 4, (431-464), (2018).
  • undefined, 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 10.1109/EMBC.2018.8513284, (1-4), (2018).
  • Incorporating historical models with adaptive Bayesian updates, Biostatistics, 10.1093/biostatistics/kxy053, (2018).
  • A Verisimilitude Framework for Inductive Inference, with an Application to Phylogenetics, The British Journal for the Philosophy of Science, 10.1093/bjps/axy054, (2018).
  • Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects, Pharmaceutical Statistics, 10.1002/pst.1843, 17, 2, (169-181), (2017).
  • Dynamic borrowing through empirical power priors that control type I error, Biometrics, 10.1111/biom.12835, 74, 3, (874-880), (2017).
  • Bayesian Design of Non-inferiority Clinical Trials Via the Bayes Factor, Statistics in Biosciences, 10.1007/s12561-017-9200-5, 10, 2, (439-459), (2017).
  • Predicting Drug Safety and Communicating Risk: Benefits of a Bayesian Approach, Toxicological Sciences, 10.1093/toxsci/kfx236, 162, 1, (89-98), (2017).
  • Bayesian statistics in educational research: a look at the current state of affairs, Educational Review, 10.1080/00131911.2017.1350636, 70, 4, (486-509), (2017).
  • Adaptive power priors with empirical Bayes for clinical trials, Pharmaceutical Statistics, 10.1002/pst.1814, 16, 5, (349-360), (2017).
  • Combining randomized and non‐randomized evidence in network meta‐analysis, Statistics in Medicine, 10.1002/sim.7223, 36, 8, (1210-1226), (2017).
  • Evaluating Generating Unit Unavailability Using Bayesian Power Priors, IEEE Transactions on Power Systems, 10.1109/TPWRS.2016.2603469, 32, 3, (2315-2323), (2017).
  • Blinded sample size recalculation in clinical trials incorporating historical data, Contemporary Clinical Trials, 10.1016/j.cct.2017.07.013, 63, (2-7), (2017).
  • Incorporation of stochastic engineering models as prior information in Bayesian medical device trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1300907, 27, 6, (1089-1103), (2017).
  • Including historical data in the analysis of clinical trials: Is it worth the effort?, Statistical Methods in Medical Research, 10.1177/0962280217694506, (096228021769450), (2017).
  • Integrating genomic signatures for treatment selection with Bayesian predictive failure time models, Statistical Methods in Medical Research, 10.1177/0962280216675373, 27, 7, (2093-2113), (2016).
  • Improving Hierarchical Models Using Historical Data with Applications in High-Throughput Genomics Data Analysis, Statistics in Biosciences, 10.1007/s12561-016-9156-x, 9, 1, (73-90), (2016).
  • A Bayesian approach to sequential meta‐analysis, Statistics in Medicine, 10.1002/sim.7052, 35, 29, (5356-5375), (2016).
  • Estimating the prevalence of multiple diseases from two‐stage hierarchical pooling, Statistics in Medicine, 10.1002/sim.6964, 35, 21, (3851-3864), (2016).
  • A bias‐corrected meta‐analysis model for combining, studies of different types and quality, Biometrical Journal, 10.1002/bimj.201900376, 0, 0, (undefined).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.